Hiroaki Nishimura

Hiroaki Nishimura

Auto-generated profile, based on publicly available information

Hiroaki Nishimura

From the Translational Medical Center (A.U., S.N., S.M., I.N.) and the National Institute of Neuroscience (A.U., S.N., W.S., H.N., S.M., T.Y., I.N.), National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SSShigeaki Suzuki
Shigeaki Suzuki
ANAtsuko Nishikawa
Atsuko Nishikawa
MKMasataka Kuwana
Masataka Kuwana
HNHiroaki Nishimura
Hiroaki Nishimura
YWYurika Watanabe
Yurika Watanabe
INIchizo Nishino
Ichizo Nishino
Anti-signal recognition particle (SRP) antibodies are used as serological markers of necrotizing myopathy, which is characterized by many necrotic and regenerative muscle fibers without or with minimal inflammatory cell infiltration. The clinical spectrum associated with anti-SRP antibodies seems to be broad. To describe the clinical characteristics, autoantibodies status, and neurological outcome associated with anti-SRP antibody. We studied clinical and laboratory findings of 100 patients with inflammatory myopathy and anti-SRP antibodies. Anti-SRP antibodies in serum were detected by the presence of 7S RNA using RNA immunoprecipitation. In addition, enzyme-linked immunosorbent assays (ELISAs) using a 54-kD protein of SRP (SRP54) and 3-hydroxyl-3-methylglutatyl-coenzyme A reductase (HMGCR) were also conducted. The mean onset age of the 61 female and 39 male patients was 51 years (range 4–82 years); duration ≥ 12 months before diagnosis was seen in 23 cases. All patients presented limbs weakness; 63 had severe weakness, 70 neck weakness, 41 dysphagia, and 66 muscle atrophy. Extramuscular symptoms and associated disorders were infrequent. Creatine kinase levels were mostly more than 1000 IU/L. Histological diagnosis showed 84 patients had necrotizing myopathy, and apparent cell infiltration was observed in 16 patients. Anti-SRP54 antibodies were undetectable in 18 serum samples with autoantibodies to 7S RNA. Anti-HMGCR antibodies were positive in 3 patients without the statin treatment, however, were negative in 5 patients with statin-exposure at disease onset. All but 3 patients were treated by corticosteroids and 62 (77 %) of these 81 patients required additional immunotherapy. After 2-years treatment, 22 (27 %) of these 81 patients had poor neurological outcomes with modified Rankin scale scores of 3–5. Multivariate analysis revealed that pediatric disease onset was associated with the poor outcomes. Anti-SRP antibodies are associated with different clinical courses and histological presentations.

21 July 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
AUAkinori Uruha
Akinori Uruha
SNSatoru Noguchi
Satoru Noguchi
WSWakiro Sato
Wakiro Sato
HNHiroaki Nishimura
Hiroaki Nishimura
SMSatomi Mitsuhashi
Satomi Mitsuhashi
INIchizo Nishino
Ichizo Nishino